IntelliPharmaCeutics Shares Up 19.5% After Co. Earlier Announced Start Of Intranasal Human Abuse Liability Studies For Oxycodone ER; Given Issue Has ~43M Shares Outstanding, Could Also Be Viewed As Low-Float Play